Center for Biologics Evaluation and Research
(重定向自CBER)
CBER's past names
view • discuss •
1880 —
–
1890 —
–
1900 —
–
1910 —
–
1920 —
–
1930 —
–
1940 —
–
1950 —
–
1960 —
–
1970 —
–
1980 —
–
1990 —
–
2000 —
–
2010 —
The present center can trace its history back to the original American public health service, which later became the NIH.
The Center for Biologics Evaluation and Research (CBER) is one of six main centers for the U.S. Food and Drug Administration (FDA), which is a part of the U.S. Department of Health and Human Services. The current Director of CBER is Dr. Karen Midthun, M.D. CBER is responsible for assuring the safety, purity, potency, and effectiveness of biologics and related products (such as vaccines, live biotherapeutics (probiotics), blood products, and cell, tissue, and gene therapies). Not all biologics are regulated by CBER. Monoclonal antibodies and other therapeutic proteins are regulated by the FDA Center for Drug Evaluation and Research (CDER).